VEN AND FREQUENCY ANALYSIS OF THE QUALITY OF PHARMACOTHERAPY OF PATIENTS WITH CHRONIC HEPATITIS

O.V.Tkachova, N.T.T.Fung, I.V.Zavadska*

National University of Pharmacy
SE «Dnipropetrovsk Medical Academy»*

Key words: drugs for the treatment of chronic hepatitis; analysis of the quality of treatment

VEN and frequency analysis were used to analyze the quality of pharmacotherapy of 79 patients with chronic hepatitis (CH) who were treated in a healthcare institution (HCI) in the city of Dnipropetrovsk in 2015. It has been found that pharmacotherapy at the HCI corresponded to main areas of the treatment specified in the clinical protocol of medical care (CPMC) to patients with CH. It has confirmed the rationality of drug prescriptions. However, a significant number of prescriptions per a patient (on average 8.9 drugs) indicates the polypharmacy in this department of the HCI. Moreover, according to the results of the formal VEN analysis a significant number of drugs with the index N (non-essential drugs) has been determined; it indicates the need for correction of drug prescription by doctors at this HCI in accordance with the current science-based medical regulations – the National Drug Formulary of Ukraine (the 7th edition) and the CPMC to patients with CH – by reducing prescriptions of non-essential drugs that are not included in these regulations. Today, being developed 11 years ago, the CPMC to patients with CH needs to be updated since it does not meet modern requirements to the current science-based medical practice guidelines that allow making the best clinical decisions in favour of the patient in accordance with the requirements of evidence-based medicine.

Chronic liver diseases are one of the most acute problems of modern gastroenterology. Annually 5% of the world population that exceeds 3 billion people suffer from chronic hepatitis (CH) [2]. In Ukraine, for the past 10 years, the prevalence of CH increased by at least 2.5 times [8]. The above facts demonstrate the importance of the problem of timely diagnosis and pharmacotherapy of hepatitis to improve organization of the specialized medical care, which has not only medical, but also social and economic significance [10].

The results of research and practical medicine show that patients with CH are at high risk of progression of the disease in liver cirrhosis and hepatocellular carcinoma [9]. Cirrhosis of the liver is one of the major causes of death of the population and occupies the 4th place in the structure of causes of death in US men over 40 [6]. In recent years in Ukraine there is a tendency to increase in morbidity and mortality from liver cirrhosis. This situation calls for the optimization of treating patients in healthcare institutions (HCI) by assessing the compliance of the CH pharmacotherapy with regulatory requirements of the Ministry of Health of Ukraine, i.e. by evaluating the quality of pharmacotherapy.

The aim of the study is to analyze the quality of the CH pharmacotherapy in patients in a hospital using VEN and frequency analysis in order to assess how well the pharmacotherapy has been conducted, or whether it corresponds to the current level of medical science and practice.

Materials and Methods

To achieve this goal it was necessary to perform the following tasks: 1) to conduct a retrospective analysis of the medication administration records of patients with chronic hepatitis; 2) to determine the frequency of prescriptions of drugs to patients with CH; 3) according to the results of the formal VEN analysis to assess the compliance of the CH therapy with the regulatory requirements of medical and technological documents of the Ministry of Health of Ukraine: the National Drug Formulary (NDF) and the CPMC to patients with CH – by reducing prescriptions of non-essential drugs that are not included in these regulations. Today, being developed 11 years ago, the CPMC to patients with CH needs to be updated since it does not meet modern requirements to the current science-based medical practice guidelines that allow making the best clinical decisions in favour of the patient in accordance with the requirements of evidence-based medicine.

O.V.Tkachova – Doctor of Pharmacy, associate professor of the Department of Pharmacoeconomics of the National University of Pharmacy (Kharkiv)

I.V.Zavadska – teaching assistant of the Department of General and Clinical Pharmacy of the Dnipropetrovsk Medical Academy
79 case histories of patients with CH, who during 12 months (January – December 2015) were treated in the Department of Gastroenterology of one of the HCI in the city of Dnipropetrovsk.

Results and Discussion

The main diagnosis in 66 patients is chronic hepatitis of the non-viral etiology and in 13 patients – chronic toxic hepatitis. Hereinafter, we combine both names of the disease under the single term “chronic hepatitis” (CH). The age of patients with CH ranged from 16 to 82 (79 patients included 35 women and 44 men). The average period of stay of the patient in the hospital was 16 days. In the case histories studied the following concomitant diagnoses, except for CH, were indicated: chronic cholecystitis (57% of patients), chronic pancreatitis (56% of patients), gastroduodenitis (15.2% of patients), hepatic encephalopathy (11.4% of patients), GERD (6.4% of patients), and ulcerative colitis (3.8% of patients). According to recommendations of the CPMC to patients with CH (Annex to the Order of the Ministry of Health No. 271 dated 13.06.2005) during the study period 700 prescriptions of drugs to all patients with CH were registered in this department; it was an average of 8.9 drugs per a patient and indicating the polypharmacy. According to recommendations of the CPMC to patients with CH (Annex to the Order of the Ministry of Health No. 271 dated 13.06.2005) [4], 4-5 INNs of drugs are used for pharmacotherapy of the underlying disease that can be characterized as pharmacotherapy, which corresponds to the WHO requirements.

In this department the prevailing areas of therapy of patients with CH were detoxification therapy (salt, detoxification solutions, glucose solutions) and pathogenetic therapy of the underlying disease (vitamins, probiotics, enterosorbents, hepatotropic drugs), which corresponded to the CPMC to patients with CH applicable at the time of study. The prevailing areas of pharmacotherapy of the concomitant gastrointestinal disease were proton pump inhibitors for chronic cholecystitis and pancreatitis (Nolpaza, Control). Fig. 1 shows the proportion of each pharmacological group of drugs (%) in the total number of prescriptions to patients with CH for 5 top leaders. The results of frequency analysis showed that the doctors in the department often preferred imported drugs as most TNs of leading drugs by the frequency of prescriptions were of foreign manufacturers.

Fig. 2 shows 10 top leaders among TNs by the frequency of prescription in the HCI. Among them the majority was used in the regimens of the complex therapy of patients diagnosed with CH (Hepamerz, Cytoflavin, 5% glucose solution, Phosphogluk, Hepasil, Lacrium, Ursolin) it was consistent with the CPMC data. But taking into account that the CPMC to patients with TH was drawn up 11 years ago (2005) today it does not meet the current requirements to science-based medical information, which allows making the best clinical decisions in favour of the patient. Current requirements of evidence-based medicine provide for continuous improvement of measures for diagnosis, treatment and prevention of diseases. For this purpose, it is necessary to introduce a new improved CPMC to patients suffering from chronic hepatitis of the non-viral etiology, and it should include methods of diagnosis and pharmacotherapy of hepatitis caused by drug-induced injury and hepatitis caused by injury from toxic substances (e.g., benzene, lead, pesticides, etc.). The new unified CPMC to patients suffer-
ing from chronic hepatitis of the non-viral etiology should be developed in accordance with the current requirements of medical and technological documents that will help the doctor to act effectively in a particular clinical situation, thus avoiding inefficient and error procedures. The new protocol should contain the classified information about the latest methods of pharmacotherapy of patients with CH caused by drug-induced injury and toxic substances, INNs of drugs for pharmacotherapy of CH, their course doses and dosage forms, as well as criteria for the treatment efficacy evaluation. The use of this approach for the treatment of patients is recommended by the clinical guidelines of the American College of Gastroenterology, which in 2014 issued the clinical guidelines for the diagnosis and treatment of drug-induced liver injuries (Drug-Induced Liver Injury Guidelines) [7].

The formal VEN analysis of the prescribed drugs was conducted to assess the compliance of the therapy of patients with CH with the regulatory requirements of medical and technological documents. According to the results of VEN analysis conducted using clinical protocols of medical care to patients it was found that 28 of 38 INNs of drugs (73.68%) were referred to the group V — vital and recommended for use in the pharmacotherapy of the underlying disease and comorbidities. 10 INNs of drugs (26.32%) and dietary supplements were absent from the CPMC for the pharmacotherapy of the underlying disease and comorbidities.

According to the results of the formal VEN analysis conducted using the NDFU it was found that most of all TNs of drugs prescribed to patients with CH, i.e. 67.0%, were present in this regulation. 39 TNs of drugs (33.0%) and 12 dietary supplements were absent from the NDFU (7th edition). Out of 39 TNs of drugs that received the index N according to the NDFU (without the evidence base) 15 TNs of drugs were used for the pharmacotherapy of CH in accordance with the current CPMC indicating the lack of conformity between the regulation and current approaches to the treatment of CH, and therefore, it needs to be updated.

The particular attention was drawn to drugs that were not included in both regulations. The following 14 TNs of drugs (11.9%) were referred to them: Osteoarthritis Max (a drug for the treatment of musculoskeletal disorders), Riboxin, Metamax (antiarrhythmic agents of class IB), Dibicor, Mildronate, Mexicor (cardiac drugs), Cyclo-3 fort, L-lysine aescinat (angio-protectors), Traumeel S (homeopathic remedy), Steatel (amino acids and their derivatives), Canephron (complex herbal preparation used in urology), Somaxon, Ceraxon, Vitamin C (medicines with the neuroprotective effect) and dietary supplements (Gepaval, Gepatomax, Livker, Gepazil, Gynolen, Probiz, Rotabiotic, Forsliv, Selen-Aktiv, B-argin, Vidzhaysar, Forsal). Most of these drugs belong to metabolic ones and can maintain the liver function to a certain extent, but today the level of evidence of the efficacy of these drugs is insufficient (C and D levels) to be included in the treatment regimen. The sufficient levels of evidence of the clinical efficacy for drugs in accordance with the current requirements are considered to be A and B levels [1].

Thus, a significant amount of drugs with the index N according to the results of VEN analysis indicates the need for correction of prescribing drugs by doctors of this HCI in accordance with the NDFU and the CPMC by reducing non-essential drugs that are not included in the regulatory medical and technological documents. Considering the fact that in Ukraine the NDFU is a modern document and is updated every year, and the CPMC to patients with CH is a significantly outdated document, it was necessary to carry out the pharmacotherapy of patients with CH in this HCI substantially corresponding to the requirements of the NDFU. Unfortunately, the results of the analysis indicate imperfect therapy of patients with CH at the HCI in Dnipropetrovsk.

CONCLUSIONS

1. Pharmacotherapy of patients with CH by the prescribed pharmacotherapeutic groups corresponded to the main areas of the treatment specified in the CPMC. It has confirmed the rationality of most prescriptions, but the average number of prescriptions per a patient is 8.9 TNs, indicating the polypharmacy in this department of the hospital.

2. Being developed 11 years ago, the CPMC to patients with CH needs to be updated since it does not meet modern requirements to the current science-based medical practice guidelines (does not contain information concerning INNs of the drugs, their course doses and dosage forms, does not contain criteria for the treatment efficacy evaluation, and it is not con-
3. Most drug prescriptions for the pharmacotherapy of patients with CH were drugs included in the NDFU of the 7th edition (67.0%) and the Ukrainian CPMC to patients with the underlying disease and comorbidities (73.68%). It has confirmed the rationality of most drug prescriptions from the clinical point of view, but indicates the need for correction of the CH pharmacotherapy at the HCI in Dnipropetrovsk.

REFERENCES

тверджает рациональность врачебных назначений. Но значительное количество назначений на 1 больного (в среднем 8,9 ЛС) свидетельствует о полипрагмазии в данном отделении УЗ. Кроме того, по результатам формального VEN-анализа установлено значительное количество ЛС с индексом N (второстепенные средства), что указывает на необходимость коррекции назначений ЛС врачами данного УЗ в соответствии с научно-медицинскими нормативными документами: Государственным формуляром лекарственных средств Украины (7 выпуск) и КПОМП больным ХГ путем уменьшения назначений второстепенных ЛС, которые в них не входят. На сегодняшний день КПОМП больным ХГ нуждается в обновлении, поскольку он разработан 11 лет назад и не соответствует современным требованиям к данным научно-медицинским нормативным документам, которые позволяют принимать оптимальные клинические решения в пользу пациента в соответствии с требованиями доказательной медицины.

Address for correspondence: 4, Valentynivska str., Kharkiv, 61168, Ukraine.
Tel. (57) 65-88-95. E-mail: ph-econom@nuph.edu.ua.
National University of Pharmacy

Received in 18.04.2016